AMOSULALOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H24N2O5S
Molecular Weight	380.459
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1

InChI

InChIKey=LVEXHFZHOIWIIP-UHFFFAOYSA-N

InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)

HIDE SMILES / InChI

Molecular Formula	C18H24N2O5S
Molecular Weight	380.459
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Amosulalol is a beta- and alpha-1 adrenoceptor-blocking agent developed for the treatment of hypertension. Amosulalol does not cross blood brain barrier and does not have adverse affect on CNS system.The drug is marketed under the name Lowgan in Japan and Korea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 169	Antagonist 2,778
Adrenergic receptor beta 87	Antagonist 2,778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567	Primary		Approved 8,429	LOWGAN

C_max

Value	Dose	Analyte	Population
0.2 μg/mL	12.5 mg single, oral	AMOSULALOL plasma	Homo sapiens
0.49 μg/mL	25 mg single, oral	AMOSULALOL plasma	Homo sapiens
1.11 μg/mL	50 mg single, oral	AMOSULALOL plasma	Homo sapiens
1.87 μg/mL	100 mg single, oral	AMOSULALOL plasma	Homo sapiens
4.09 μg/mL	150 mg single, oral	AMOSULALOL plasma	Homo sapiens
0.311 μg/mL	30 mg single, oral	AMOSULALOL plasma	Homo sapiens
0.498 μg/mL	30 mg single, oral	AMOSULALOL plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
1.67 μg × h/mL	12.5 mg single, oral	AMOSULALOL plasma	Homo sapiens
3.64 μg × h/mL	25 mg single, oral	AMOSULALOL plasma	Homo sapiens
6.07 μg × h/mL	50 mg single, oral	AMOSULALOL plasma	Homo sapiens
12.58 μg × h/mL	100 mg single, oral	AMOSULALOL plasma	Homo sapiens
22.09 μg × h/mL	150 mg single, oral	AMOSULALOL plasma	Homo sapiens
2.661 μg × h/mL	30 mg single, oral	AMOSULALOL plasma	Homo sapiens
3.287 μg × h/mL	30 mg single, oral	AMOSULALOL plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
4.4 h	12.5 mg single, oral	AMOSULALOL plasma	Homo sapiens
5.2 h	25 mg single, oral	AMOSULALOL plasma	Homo sapiens
4.8 h	50 mg single, oral	AMOSULALOL plasma	Homo sapiens
5.6 h	100 mg single, oral	AMOSULALOL plasma	Homo sapiens
5.7 h	150 mg single, oral	AMOSULALOL plasma	Homo sapiens
3.6 h	30 mg single, oral	AMOSULALOL plasma	Homo sapiens
3.1 h	30 mg single, oral	AMOSULALOL plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
2%			AMOSULALOL plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
150 mg single, oral Highest studied dose	healthy, ADULT	Other AEs: Dizziness...
0.16 mg/kg single, intravenous Highest studied dose	healthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Dizziness	grade 1, 50%	150 mg single, oral Highest studied dose	healthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection.	2005 Apr 25	15734149

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The daily dosage is from 40 mg to 60 mg.

Route of Administration: Oral

In Vitro Use Guide

Smooth muscle cells of the guinea-pig mesenteric artery and vein and the main pulmonary artery were incubated with amosulalol. In the mesenteric artery, the noradrenaline-induced depolarization was inhibited significantly by amosulalol in concentrations over 10(-8)M, and the depolarization ceased by amosulalol in concentrations over 10(-7)M. In the pulmonary artery, membrane depolarizations produced by 5 x 10(-6)M noradrenaline were significantly reduced by amosulalol in concentrations over 10(-7)M, and ceased after pretreatment with 10(-5)M amosulalol. In the mesenteric vein, membrane depolarization produced by exogenously applied noradrenaline (10(-5)M) was not blocked by amosulalol, up to 10(-5)M.

Substance Class	Chemical
Record UNII	C69JI1BAU8
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

AMOSULALOL

Official Name

English

AMOSULALOL [MI]

Common Name

English

(±)-5-(1-HYDROXY-2-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)ETHYL)-O-TOLUENESULFONAMIDE

Common Name

English

Amosulalol [WHO-DD]

Common Name

English

amosulalol [INN]

Common Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Classification Tree

Code System

Code

Adrenergic Agent

NCI_THESAURUS

C72900

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

EPA CompTox

DTXSID90868893

PRIMARY

ChEMBL

CHEMBL152231

PRIMARY

NCI_THESAURUS

C72916

PRIMARY

MESH

C032473

PRIMARY

INN

5409

PRIMARY

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					4O4S698PEE

AMOSULALOL HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					C69JI1BAU8

AMOSULALOL

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound